Last reviewed · How we verify
CD19 and CD22 targeted prime CAR- T cells — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
CD19 and CD22 targeted prime CAR- T cells (CD19 and CD22 targeted prime CAR- T cells) — Chongqing Precision Biotech Co., Ltd.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| CD19 and CD22 targeted prime CAR- T cells TARGET | CD19 and CD22 targeted prime CAR- T cells | Chongqing Precision Biotech Co., Ltd | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- CD19 and CD22 targeted prime CAR- T cells CI watch — RSS
- CD19 and CD22 targeted prime CAR- T cells CI watch — Atom
- CD19 and CD22 targeted prime CAR- T cells CI watch — JSON
- CD19 and CD22 targeted prime CAR- T cells alone — RSS
Cite this brief
Drug Landscape (2026). CD19 and CD22 targeted prime CAR- T cells — Competitive Intelligence Brief. https://druglandscape.com/ci/cd19-and-cd22-targeted-prime-car-t-cells. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab